← Back to Home

A New Pulmonary Fibrosis Drug Turns Back Protein Age Clocks. How Far Are We From Proving Age Reversal in Humans?

Early trial data for rentosertib show younger protein signatures, but “up to six years” is a model estimate and does not yet mean that patients have actually become younger or are living healthier lives.

By SURL BioNews

Could blood also reveal signs of the body becoming younger during treatment for lung disease? A study involving patients with idiopathic pulmonary fibrosis analyzed trial samples from the experimental drug rentosertib using six protein age models and found decreases in predicted age in some treatment groups. This connects disease treatment with aging research, while raising a key question: how much of the clock reversal in these models reflects changes in aging, and how much merely reflects changes in disease status?

The paper, published September 7 in *Nature Biotechnology*, analyzed serum data covering 2,841 proteins from 42 patients in a 12-week Phase 2a trial. This was an extended analysis of existing clinical trial data, rather than an anti-aging trial that separately recruited healthy adults. The “proteomic aging clocks” used in the study are models that estimate age-related states from combinations of blood proteins. A decrease in their readings means that the samples show statistically younger characteristics; it cannot be directly translated into years of restored bodily function.

All six models detected an overall signal of lower predicted age following treatment, but the effects varied by dose, time point, and model. Of 54 comparisons between treatment groups and placebo, 21 met the study’s threshold of a Q value below 0.10 after correction for multiple comparisons. The most consistent results across models appeared at week 4, particularly in the group receiving 30 milligrams twice daily. The group receiving 60 milligrams once daily showed decreases in predicted age of approximately 2.71 to 3.46 years on four clocks trained on chronological age.

The “up to six years” in news headlines comes from developer Insilico Medicine’s description of results from particular clocks. The company said the peak reduction was approximately three to four years of predicted age, reaching six years in one model. This was not a result shared by all patients, all models, or the entire treatment period, nor does it mean a six-year increase in lifespan. By week 12, fewer comparisons met the statistical threshold; the study cannot yet answer how long these changes may last.

Rentosertib is a small-molecule drug candidate targeting the TNIK kinase, being developed for idiopathic pulmonary fibrosis. Insilico Medicine said AI first helped identify TNIK as a target associated with fibrosis and aging biology, and was then used to design molecules that inhibit it. The process from target identification to selection of a preclinical drug candidate took approximately 18 months. That period describes the drug discovery stage; evidence of efficacy in humans, long-term safety, and the evidence needed for approval must still be established through clinical research.

The hardest issue to disentangle is that improvements in lung disease and aging signals may inherently overlap. The paper’s authors explicitly stated that protein clocks alone cannot separate the effects of the two. Dung Trinh, a physician who was not involved in the study, also told *Medical News Today* that the sample was small, observation lasted only 12 weeks, and all participants had pulmonary fibrosis, meaning the protein changes could reflect improvements in their underlying disease. The paper also disclosed that several authors were executives or employees of the drug’s developer. These exploratory findings await subsequent independent validation.

The value of this work lies in demonstrating how aging-related measurements can be incorporated into disease trials, allowing researchers to track a drug’s effects on different biological processes simultaneously. Whether it can provide meaningful evidence of an anti-aging effect still comes back to patients: larger studies with longer follow-up must establish whether lower clock scores are accompanied by sustained improvements in function and acceptable risks. As Zeeshan Khan, a geriatrician who was not involved in the study, emphasized, what truly matters is whether patients can live healthier lives with better function.

References

  1. International Business Times UK
  2. Nature Biotechnology
  3. Insilico Medicine via PR Newswire
  4. Medical News Today